167 related articles for article (PubMed ID: 26611771)
21. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.
Catalona WJ; Smith DS; Wolfert RL; Wang TJ; Rittenhouse HG; Ratliff TL; Nadler RB
JAMA; 1995 Oct; 274(15):1214-20. PubMed ID: 7563511
[TBL] [Abstract][Full Text] [Related]
22. Impact of PSA levels on second-round screening for the development of prostate cancer in men with low baseline PSA levels (≤2.0 mg/ml).
Kitagawa Y; Sawada K; Urata S; Izumi K; Ueno S; Kadono Y; Konaka H; Mizokami A; Namiki M
Anticancer Res; 2014 Nov; 34(11):6739-46. PubMed ID: 25368284
[TBL] [Abstract][Full Text] [Related]
23. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
[TBL] [Abstract][Full Text] [Related]
24. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.
Catalona WJ; Smith DS; Ornstein DK
JAMA; 1997 May; 277(18):1452-5. PubMed ID: 9145717
[TBL] [Abstract][Full Text] [Related]
25. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
[TBL] [Abstract][Full Text] [Related]
26. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
Culp S; Porter M
BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
[TBL] [Abstract][Full Text] [Related]
27. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.
Thompson IM; Ankerst DP; Chi C; Lucia MS; Goodman PJ; Crowley JJ; Parnes HL; Coltman CA
JAMA; 2005 Jul; 294(1):66-70. PubMed ID: 15998892
[TBL] [Abstract][Full Text] [Related]
28. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
Roobol MJ; Kranse R; de Koning HJ; Schröder FH
Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
[TBL] [Abstract][Full Text] [Related]
29. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
[TBL] [Abstract][Full Text] [Related]
30. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
[TBL] [Abstract][Full Text] [Related]
31. Changes in serum prostate-specific antigen levels and the identification of prostate cancer in a large managed care population.
Wallner LP; Frencher SK; Hsu JW; Chao CR; Nichol MB; Loo RK; Jacobsen SJ
BJU Int; 2013 Jun; 111(8):1245-52. PubMed ID: 23320750
[TBL] [Abstract][Full Text] [Related]
32. Prostate-specific antigen kinetics in localized and advanced prostate cancer.
Fitzpatrick JM; Banu E; Oudard S
BJU Int; 2009 Mar; 103(5):578-87. PubMed ID: 19210674
[TBL] [Abstract][Full Text] [Related]
33. Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial.
Pinsky PF; Andriole GL; Kramer BS; Hayes RB; Prorok PC; Gohagan JK;
J Urol; 2005 Mar; 173(3):746-50; discussion 750-1. PubMed ID: 15711261
[TBL] [Abstract][Full Text] [Related]
34. Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years: A Secondary Analysis of a Cohort in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Kovac E; Carlsson SV; Lilja H; Hugosson J; Kattan MW; Holmberg E; Stephenson AJ
JAMA Netw Open; 2020 Jan; 3(1):e1919284. PubMed ID: 31940039
[TBL] [Abstract][Full Text] [Related]
35. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
Hattangadi JA; Chen MH; D'Amico AV
BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy.
Gerber GS; Gornik HL; Goldfischer ER; Chodak GW; Rukstalis DB
J Urol; 1998 Apr; 159(4):1243-6. PubMed ID: 9507845
[TBL] [Abstract][Full Text] [Related]
37. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml.
Morote J; Raventós CX; Lorente JA; Lopez-Pacios MA; Encabo G; de Torres I; Andreu J
J Urol; 1997 Aug; 158(2):502-4. PubMed ID: 9224333
[TBL] [Abstract][Full Text] [Related]
38. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations.
Eastham JA; Riedel E; Scardino PT; Shike M; Fleisher M; Schatzkin A; Lanza E; Latkany L; Begg CB;
JAMA; 2003 May; 289(20):2695-700. PubMed ID: 12771116
[TBL] [Abstract][Full Text] [Related]
39. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.
Oesterling JE; Jacobsen SJ; Chute CG; Guess HA; Girman CJ; Panser LA; Lieber MM
JAMA; 1993 Aug; 270(7):860-4. PubMed ID: 7688054
[TBL] [Abstract][Full Text] [Related]
40. The digital rectal examination (DRE) remains important - outcomes from a contemporary cohort of men undergoing an initial 12-18 core prostate needle biopsy.
Palmerola R; Smith P; Elliot V; Reese CT; Mahon FB; Harpster LE; Icitovic N; Raman JD
Can J Urol; 2012 Dec; 19(6):6542-7. PubMed ID: 23228289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
